Forbes
Forbes contributor Howard Gleckman highlights a study by Prof. Amy Finkelstein that shows only five percent of Medicare spending goes toward end-of-life costs. Gleckman writes that the study supports the argument that “using spending in the last year of life as a proxy for futile care is deeply flawed—because we are very bad at predicting who is going to die and who is not.”